Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
首次招募和首例受试者用药预计将很快将在荷兰罗特丹的 Erasmus Medical Center 进行 管理层在以下视频中对本公告及其意义进行了讨论，视频链接为：视频 奥卡拉，佛罗里达州, Jan. 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.（美国 NYSE：AIM）（简称“AIM”或“公司”）今日宣布，在 Erasmus...
-
First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands Management discusses the announcement and what this means here: video OCALA, Fla.,...
-
癌･ME/CFS治療薬Ampligenの米国における独占権を2039年まで延長 経営陣が特許の取得とその意味について簡単な動画で説明している。 こちら フロリダ州オカラ発 , Nov. 29, 2023 (GLOBE NEWSWIRE) -- AIMイムノテック (AIM ImmunoTech Inc.) (NYSE American: AIM) (「AIM」または「同社」)...
-
Ampligen 治疗癌症和肌痛性脑脊髓炎 (ME)/慢性疲劳综合征 (CFS) 的某些美国独家权利延长至 2039 年 管理层在一段简短的视频中讨论了专利的颁发及其意义：点击此处 佛罗里达州奥卡拉, Nov. 29, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American:...
-
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 28, 2023 ...
-
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 27, 2023 ...
-
No severe adverse events reported to date Topline data expected as early as Q1 2024 OCALA, Fla., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”)...
-
– Highlights continued execution across Ampligen® clinical development programs – Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024 – Will...
-
OCALA, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of results from the Phase 1 study at Roswell Park...
-
OCALA, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss...